2025 Q4 -tulosraportti
66 päivää sitten
‧49 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sitten · MuokattuWhat do people think about the timing for a partnership agreement? Nothing will probably happen until after the Medicare application has been submitted? Because only then has the final sprint truly begun? Could it be that a little is revealed without disclosing which partner, now at the next opportunity in May? There is so much uncertainty in this, which otherwise has some more predictable aspects. As the CEO has to keep many cards close to their chest. The Medicare application is probably roughly promised to be submitted in the summer of 2026, at least. AI-quotes: "The Specific Month: While "mid-2026" technically spans May to July, the most recent analyst updates (Carlsquare, Feb 2026) and company guidance point toward a push to have the application finalized and submitted by June or July 2026. The Prerequisite: The company is currently completing the "clinical utility survey data" in the first half of 2026. This data is the final piece of the puzzle needed to prove to Medicare (and regional MACs) that doctors actually change their medical behavior based on the PancreaSure results." "The "Two-Path" Strategy: Borcherding clarified that they are pursuing short-term survey data (ready by mid-2026) to get the application in, while simultaneously running longer-term, NIH-funded clinical trials to solidify the evidence for more conservative payers later." "Why the "Specific Month" Matters If they hit the June/July submission window, it typically triggers a review period that could lead to a Local Coverage Determination (LCD) late in the year or early 2027. If you are looking for a definitive "reveal," the Annual General Meeting (AGM) on May 13, 2026, is where Borcherding will likely be pressed by shareholders to confirm if they are still on track for that "mid-year" submission."- ·1 päivä sitten · Muokattu"Just a reminder that the Swedish stock exchange closes at 1 PM today", or words to that effect.
- ·2 päivää sittenCool that the stock is rising on a red stock market day for many other stocks 🥳 I wonder if it's that teacup-chat at the Placera-forum that has contributed?·1 päivä sitten · MuokattuI'm starting to think that the market prefers to keep the stock cheap at any cost? So that this cup and handle pattern doesn't materialize? And technical analysis is often fuzzy matter anyway. But there are indeed catalyst points before May 7th, I would think. Because it is here that people must make their final own choices about whether they believe the news will drive the price up or down on May 7th. Here is the link to the one who tried to predict on the Placera-forum: https://forum.placera.se/inlagg/0395ae1e-a47b-4674-bceb-be55a0ebe776
- ·23.4. · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."
- ·23.4.Pity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
66 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuWhat do people think about the timing for a partnership agreement? Nothing will probably happen until after the Medicare application has been submitted? Because only then has the final sprint truly begun? Could it be that a little is revealed without disclosing which partner, now at the next opportunity in May? There is so much uncertainty in this, which otherwise has some more predictable aspects. As the CEO has to keep many cards close to their chest. The Medicare application is probably roughly promised to be submitted in the summer of 2026, at least. AI-quotes: "The Specific Month: While "mid-2026" technically spans May to July, the most recent analyst updates (Carlsquare, Feb 2026) and company guidance point toward a push to have the application finalized and submitted by June or July 2026. The Prerequisite: The company is currently completing the "clinical utility survey data" in the first half of 2026. This data is the final piece of the puzzle needed to prove to Medicare (and regional MACs) that doctors actually change their medical behavior based on the PancreaSure results." "The "Two-Path" Strategy: Borcherding clarified that they are pursuing short-term survey data (ready by mid-2026) to get the application in, while simultaneously running longer-term, NIH-funded clinical trials to solidify the evidence for more conservative payers later." "Why the "Specific Month" Matters If they hit the June/July submission window, it typically triggers a review period that could lead to a Local Coverage Determination (LCD) late in the year or early 2027. If you are looking for a definitive "reveal," the Annual General Meeting (AGM) on May 13, 2026, is where Borcherding will likely be pressed by shareholders to confirm if they are still on track for that "mid-year" submission."
- ·1 päivä sitten · Muokattu"Just a reminder that the Swedish stock exchange closes at 1 PM today", or words to that effect.
- ·2 päivää sittenCool that the stock is rising on a red stock market day for many other stocks 🥳 I wonder if it's that teacup-chat at the Placera-forum that has contributed?·1 päivä sitten · MuokattuI'm starting to think that the market prefers to keep the stock cheap at any cost? So that this cup and handle pattern doesn't materialize? And technical analysis is often fuzzy matter anyway. But there are indeed catalyst points before May 7th, I would think. Because it is here that people must make their final own choices about whether they believe the news will drive the price up or down on May 7th. Here is the link to the one who tried to predict on the Placera-forum: https://forum.placera.se/inlagg/0395ae1e-a47b-4674-bceb-be55a0ebe776
- ·23.4. · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."
- ·23.4.Pity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
66 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuWhat do people think about the timing for a partnership agreement? Nothing will probably happen until after the Medicare application has been submitted? Because only then has the final sprint truly begun? Could it be that a little is revealed without disclosing which partner, now at the next opportunity in May? There is so much uncertainty in this, which otherwise has some more predictable aspects. As the CEO has to keep many cards close to their chest. The Medicare application is probably roughly promised to be submitted in the summer of 2026, at least. AI-quotes: "The Specific Month: While "mid-2026" technically spans May to July, the most recent analyst updates (Carlsquare, Feb 2026) and company guidance point toward a push to have the application finalized and submitted by June or July 2026. The Prerequisite: The company is currently completing the "clinical utility survey data" in the first half of 2026. This data is the final piece of the puzzle needed to prove to Medicare (and regional MACs) that doctors actually change their medical behavior based on the PancreaSure results." "The "Two-Path" Strategy: Borcherding clarified that they are pursuing short-term survey data (ready by mid-2026) to get the application in, while simultaneously running longer-term, NIH-funded clinical trials to solidify the evidence for more conservative payers later." "Why the "Specific Month" Matters If they hit the June/July submission window, it typically triggers a review period that could lead to a Local Coverage Determination (LCD) late in the year or early 2027. If you are looking for a definitive "reveal," the Annual General Meeting (AGM) on May 13, 2026, is where Borcherding will likely be pressed by shareholders to confirm if they are still on track for that "mid-year" submission."
- ·1 päivä sitten · Muokattu"Just a reminder that the Swedish stock exchange closes at 1 PM today", or words to that effect.
- ·2 päivää sittenCool that the stock is rising on a red stock market day for many other stocks 🥳 I wonder if it's that teacup-chat at the Placera-forum that has contributed?·1 päivä sitten · MuokattuI'm starting to think that the market prefers to keep the stock cheap at any cost? So that this cup and handle pattern doesn't materialize? And technical analysis is often fuzzy matter anyway. But there are indeed catalyst points before May 7th, I would think. Because it is here that people must make their final own choices about whether they believe the news will drive the price up or down on May 7th. Here is the link to the one who tried to predict on the Placera-forum: https://forum.placera.se/inlagg/0395ae1e-a47b-4674-bceb-be55a0ebe776
- ·23.4. · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."
- ·23.4.Pity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt